Is Recombinant Growth Hormone Therapy Associated With Increased Intraoccular Pressure?

Assaf-Harofeh Medical Center100 enrolled

Overview

Recombinant growth hormone is a common therapy in the pediatric population. A number of associated side effects have been described. Several years ago, a case report was published concerning a child that was treated with RGH and developed acute glaucoma. To date no study has evaluated the connection.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Growth Hormone Treatment Glaucoma

Interventions

Measuring intraoccular pressureOTHER

Measurement of intraoccular pressure by tonometry

Eligibility

Sex: ALLMin age: 6 YearsMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 6-18 years * treatment with recombinant growth hormone Exclusion Criteria: * Underlying Chronic diseases * Family history of eye diseases * elevated occular pressure prior to starting treatment

Locations (1)

Assaf harofeh medical center

Ẕerifin, Israel

Outcomes

Primary Outcomes

Intraoccular pressure in children treated with RGH

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.